BeyondSpring Inc.
BYSI · XNASCIK 1677940fmd_1YS17SJSQJZAJ8FD4X1KK9STHAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Jun 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Research and development | 10 | 89 | 52 | 31 | 42 | 37 | 26 | 7 | 3 | 4 |
| Selling, general and administrative | 2 | 9 | 6 | 9 | 23 | 31 | 13 | 8 | 6 | 5 |
| Compensation and benefits | – | – | – | – | – | – | – | 6 | 5 | 3 |
| Operating income | (12) | (98) | (58) | (40) | (64) | (66) | (37) | (15) | (9) | (9) |
| Interest expense | – | – | – | 0 | 0 | 0 | 0 | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | 1 | 0 | 0 | 0 | 1 | 1 | – | – | – |
| Income before taxes | (13) | (96) | (57) | (40) | (64) | (65) | (36) | (14) | (9) | (9) |
| Income tax expense | – | – | – | 0 | 0 | 4 | 0 | (0) | 0 | 0 |
| Net income from continuing operations | – | – | – | (40) | (64) | (68) | (36) | (14) | (9) | (9) |
| Net income | (12) | (92) | (55) | (38) | (61) | (64) | (33) | (21) | (11) | (1) |